Pharma: Clinic Roundup
Tuesday, June 5, 2012
Bristol-Myers Squibb Co., of New York, reported four-year results from the long-term extensions of the BENEFIT and BENEFIT-EXT trials evaluating Nulojix (belatacept), its selective T-cell co-stimulation blocker indicated for the prophylaxis of organ rejection in adult Epstein-Barr virus-seropositive patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.